The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone.

Krister BambergLena William-OlssonUlrika JohanssonRasmus Jansson-LöfmarkJudith Hartleib-Geschwindner

Published in: Journal of the renin-angiotensin-aldosterone system : JRAAS (2019)

The data suggest that the contrasting effects of AZD9977 on urinary electrolyte excretion observed in rats and humans are due to the use of the synthetic mineralocorticoid fludrocortisone. Future clinical studies are required to confirm the reduced electrolyte effects of AZD9977 and the subsequent lower predicted hyperkalemia risk.

Keyphrases

ionic liquid
ion batteries
electronic health record
current status
angiotensin ii
binding protein
data analysis